+44 20 8123 2220
info@marketpublishers.com

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

https://marketpublishers.com/r/IED598E74D3EN.html
Date: January 2018
Pages: 252
Price: US$ 2,800.00 (Single User License)
ID: IED598E74D3EN

Abstracts

It is estimated that there are 3-4 times more intracellular targets than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody (mAb) therapies. Since many of these targets are not enzymes or surface receptoers with readily druggable pockets, these important oncogenic proteins cannot be easily inhibited with small molecules. Thus, intracellular cancer-specific proteins, such as mutated oncogene products, transcription factors, protein adapters, and other nontraditional targets, remain inaccessible to current technologies used for FDA-approved drugs.

Therefore, novel technologies are needed to address historically undruggable targets and complex mechanisms, such as intracellular protein-protein interactions like p53 or Ras, ?-catenin and Myc.

This report „Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends“ brings you up-to-date regarding key technologies

for identification and validation of intracellular targets,

for generation of T-cell receptors (TCR) and TCR fusion proteins,

for discovery of TCR-like antibodies, and

+44 20 8123 2220
info@marketpublishers.com

for construction of cell-penetrating peptides, proteins and antibodies.

The report furthermore describes the profiles of leading product candidates created by these technologies. The technology companies are presented and analyzed. Deals between Big Pharma and technology companies as well as collaboration and licensing deals between technology companies are highlighted. The value of technologies and product candidates are discussed regarding company acquisition prices, economic deal terms and financing rounds.

What will you find in the report?

Description and comparison of technologies for

- Discovery and validation of intracellular targets;
- Discovery and optimization of T-Cell Receptors (TCRs);
- Generation of TCR-like or TCR-mimic antibodies;
- Generation of TCR fusion proteins
- Generation of cell-penetrating peptides, proteins and antibodies.

Presentation and discussion of profiles of selected product candidates:

- TCRL antibodies and TCR fusion proteins; and
- Cell-penetrating peptides, miniproteins and single domain and Ig antibodies

Stakeholder analysis based on profiles of 45 companies active in the field Analysis of partnering deals and financing rounds

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

6 STAKEHOLDER ANALYSIS & COMPANY PROFILES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

Tables

TABLES IN THE REPORT

+44 20 8123 2220
info@marketpublishers.com

Collaboration and Licensing Agreements between Technology Companies
Financing Sources of Technology Companies in the Field

COMPANIES MENTIONED IN THE REPORT

AbbVie
AbeXXa Biologics
Adicet Bio (Applied Immune Technologies)
Affimed Therapeutics
Agenus
Aileron Therapeutics
Amgen
Astellas Pharma
AstraZeneca
Atreca
BioNTech
Boehringer Ingelheim
Complix
Elasmogen
Eli Lilly
Eureka Therapeutics
Feldan Therapeutics
Fog Pharmaceuticals
Gadeta
Gilead Sciences (Kite Pharma)
GlaxoSmith-Kline
Immatics Biotechnologies
Immunocore
Innovative Targeting Solutions (ITS)
Janssen Biotech
Juno Therapeutics
MD Anderson Cancer Center
Medigene
Merck
Morphosys
NantCell (Altor Bioscience)
Nextera
Novartis
Orum Pharmaceuticals

+44 20 8123 2220
info@marketpublishers.com

Patrys
Pure MHC
Pure MHC
Receptor Logic (now Pure MHC)
Regeneron Pharmaceuticals
Roche
Singh Biotechnology
Sorrento Therapeutics & LA Cell
Timmune Biotech
Xencor
ZIOPHARM Oncology
Zymeworks

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Product link: https://marketpublishers.com/r/IED598E74D3EN.html

Price: US$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/IED598E74D3EN.html